Agendia's MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer

Huntington Beach, California and Amsterdam (ots/PRNewswire)
-- Agendia, a world leader in molecular cancer diagnostics, today
announced MammaPrint(R)'s ability to predict response to neoadjuvant
chemotherapy in breast cancer.

Dr. Laura van 't Veer, from the Netherlands Cancer Institute,
presented the data at the 2008 San Antonio Breast Cancer Symposium
(SABCS) during the session Molecular profiling for guiding
therapeutic decisions. The study analyzed the association between the
pathological complete response (pCR) rate and the results of the
MammaPrint test.

"Physicians are increasingly supportive of MammaPrint in clinical
practice because they believe it provides them with invaluable
information for patient treatment planning. MammaPrint's ability to
accurately determine high risk patient responsiveness to chemotherapy
both confirm and speak to the confidence physicians express in this
state-of-the-art genomic breast cancer test," commented Dr. Richard
Bender, Chief Medical Officer of Agendia and a life-long practicing
oncologist who made a career at the NCI, Kaiser Permanente and Quest
Diagnostics.

Findings in the neoadjuvant setting support MammaPrint's
predictive power for chemotherapy response, in addition to its
previously demonstrated prognostic value for early stage disease. The
achievement of pCR is a valuable indicator for long-term response in
this clinical setting.

A consecutive series of 167 patients who received neoadjuvant
chemotherapy for stage II or III breast cancer were analyzed to
assess MammaPrint's potential predictive power. 20 percent of the 144
patients in the poor prognosis signature group achieved a pCR,
whereas none of the patients with a good prognosis signature achieved
a pCR. After a median follow-up of 25 months, 19 relapses were seen
in the poor signature and none in the good signature group. These
findings suggest tumors with a poor prognosis MammaPrint signature
are sensitive to chemotherapy.

About MammaPrint(R)

MammaPrint is the first 'in vitro diagnostic multivariate index
assay' (IVDMIA) cleared by the U.S. Food and Drug Administration
(FDA). FDA clearance requires clinical and analytical validation and
reporting systems to ensure patient safety issues are addressed.
Highly accurate, MammaPrint identifies patients with early metastasis
- those patients who are likely to develop metastases within five
years following surgery. Several authoritative studies have shown
that chemotherapy particularly reduces early metastasis risk. In
planning treatment, the MammaPrint test result provides a doctor with
a clear rationale to assess the benefit of adjuvant chemotherapy in
addition to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CLIA-certified
service laboratory. All other breast cancer recurrence assays
currently marketed have not been subject to the rigorous FDA
clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine
revolution, striving to bring more effective, individualized
treatments within reach of patients. Building on a cutting edge
genomics platform for tumor gene expression profiling, the company's
tests aim to help physicians more accurately tailor cancer
treatments. The company markets four products, with several new
genomic tests under development. In addition, Agendia collaborates
with pharmaceutical companies to develop highly effective
personalized drugs in the area of oncology. Agendia is based in
Huntington Beach, California, and in Amsterdam, The Netherlands. For
more information please visit http://www.agendia.com.

ots Originaltext: Agendia BV
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Media contacts: Hans Herklots, Head of Corporate Communications,
Agendia, +31-20-462-1557 Office, +31-620-083-509 Mobile,
hans.herklots@agendia.com. Valerie Delva, Account Executive, Ricochet
Public Relations, +1-212-679-3300 x131 Office, +1-917-975-3191
Mobile, vdelva@ricochetpr.com